IR800 IAB2MA
Alternative Names: IR800-IAB2MALatest Information Update: 13 Jan 2023
At a glance
- Originator ImaginAb Inc
- Class Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Prostate cancer
- Preclinical Renal cancer
Most Recent Events
- 25 Nov 2022 Phase-I clinical trials in Prostate cancer (Diagnosis) in Unknown location (unspecified route) (ImaginAB pipeline, November 2022)
- 25 Nov 2022 Preclinical trials in Renal cancer (Diagnosis) in USA (unspecified route) (ImaginAB pipeline, November 2022)